Is the market overreacting to the coronavirus? Why do so many clinical trials go unfilled? And how do you pronounce “Martin Shkreli”?
We discuss all that and more on this, the 100th episode of “The Readout LOUD,” STAT’s biotech podcast. First, we delve into the stock market’s frenetic reaction to the novel coronavirus outbreak and how it’s affecting biotech companies. Then, we talk to Todd Mercer, a patient from Michigan with a rare type of cancer, about how difficult it can be to enroll in a clinical trial. Later, we revisit the first episode of this podcast to update the big stories of yesteryear and discover just how embarrassed we should be. Finally, we field questions from listeners, covering genetically engineered pets, putting a dollar value on human life, and the importance of gossip.
And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email firstname.lastname@example.org.
Interested in sponsoring a future episode of “The Readout LOUD”? Email us at email@example.com.